申请人:Exelixis, Inc.
公开号:US07973061B2
公开(公告)日:2011-07-05
The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).
本发明涉及公式I的化合物,其中L、X、Y、Z、R1、R2、R3和R4在此定义。该发明还提供了使用这些化合物抑制激酶,更具体地是ALK激酶的方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动,如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径,并且该发明包括含有这些化合物的组合物,以及使用它们治疗激酶依赖性疾病和病况的方法;(公式I)。